Key result
Benzbromarone inhibits platelet activation and reduces thrombosis comparably to aspirin and clopidogrel in mice.
Why the study?
Clinically available inhibitors of heat shock protein 47 (HSP47) for antiplatelet therapy in ischemic stroke are lacking, and whether the urate-lowering drug benzbromarone exerts antithrombotic effects by targeting platelet HSP47 remained unclear.
Does benzbromarone reduce platelet activation, arterial thrombosis, and cerebral ischemia-reperfusion injury in mouse models?
Does benzbromarone reduce platelet activation, arterial thrombosis, and cerebral ischemia-reperfusion injury in mouse models?
Benzbromarone acts as a clinically available HSP47 inhibitor that suppresses platelet activation, arterial thrombosis, and cerebral ischemia-reperfusion injury in mice without obvious bleeding risk.
Answers are grounded in this paper and cite their sources.
Benzbromarone may represent a new antiplatelet strategy in stroke models; leaves open translation of HSP47 targeting to human therapy.
Antiplatelet therapy is a major strategy for ischemic stroke. Studies have identified heat shock protein 47 (HSP47) as a safe and effective novel target for antiplatelet therapy, but clinically available HSP47 inhibitors remain lacking. Benzbromarone, a commonly used urate-lowering drug, has been reported to bind HSP47; however, whether it exerts antithrombotic effects by targeting platelet HSP47 remains unclear. In this study, cellular thermal shift assay and drug affinity responsive target stability assay demonstrated that benzbromarone directly interacted with platelet HSP47 and enhanced its stability. Benzbromarone disrupted the HSP47-collagen interaction and selectively inhibited collagen-induced platelet adhesion, spreading, aggregation, P-selectin expression, and reactive oxygen species production, with little effect on thrombin- or arachidonic acid-induced aggregation. In a FeCl 3 -induced mouse carotid artery thrombosis model, benzbromarone dose-dependently prolonged occlusion time and reduced thrombus formation, with efficacy comparable to aspirin and clopidogrel, without obvious bleeding risk, coagulation disturbance, or hepatic or renal toxicity at effective doses. Mechanistically, benzbromarone inhibited phosphorylation of Syk, PKC, and PLCγ2 downstream of the collagen-GPVI signaling pathway. Importantly, its antiplatelet and antithrombotic effects were largely abolished in platelet-specific HSP47 knockout mice, confirming the dependence on platelet HSP47. In a middle cerebral artery occlusion model, benzbromarone reduced cerebral microthrombosis, infarct volume, and neurological deficits, and this neuroprotection was largely HSP47-dependent. Together, these findings support benzbromarone as a clinically available HSP47-targeting candidate that suppresses platelet activation, arterial thrombosis, and cerebral ischemia-reperfusion injury, warranting further evaluation for ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied Arterial thrombosis and cerebral ischemia-reperfusion injury / ischemic stroke. Benzbromarone vs. Aspirin and clopidogrel was evaluated on Platelet activation, arterial thrombus formation, occlusion time, cerebral microthrombosis, infarct volume, and neurological deficits. Benzbromarone targets platelet HSP47 to inhibit collagen/GPVI-mediated platelet activation, reducing arterial thrombosis and cerebral infarct volume in mice comparably to aspirin and clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: